06-05-06

CASE PN/4-32761A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727271920 US

Express Mail Label Number

June 2, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

BARSKE ET AL.

APPLICATION NO: 10/538,201

FILED: JUNE 10, 2005

FOR: ANTIBODY ("11C7") ANTI NOGO AND ITS PHARMACEUTICAL

USE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the title and the "Foreign Applications" section was omitted. On page 2 of the enclosed Declaration, it shows that the application does claim benefit of Great Britain priority application 0228832.2, filed on December 10, 2002.

Please issue a corrected filing receipt listing these areas as follows:

Title

Antibody ("11C7") Anti Nogo A And Its Pharmaceutical Use

Foreign Applications
Great Britain 0228832.2 10/12/2002

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7951 Date: Respectfully submitted

Peter J. Waibel Attorney for Applicants Reg. No. 43,228



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS Adeasdria, Vrignia 22313-1450 www.uspto.gov

FILING OR 371 ART UNIT FIL FEE REC'D APPL NO. ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS (c) DATE 03/08/2006 1614 18 10/538,201

JUN 0 2 2006

PN/4-32761A

CONFIRMATION NO. 1795

1095 NOVARTIS
CORPORATE INTELLECTUAL PROPER

OF A 204/3 **EAST HANOVER, NJ 07936-1080**

FILING RECEIPT OC000000018496913*

Date Mailed: 05/01/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon, If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Carmen Barske, Loerrach, GERMANY;

Anis Khusro Mir, Bartenheim, FRANCE;

Thomas Oertle, Gerra/Gambarogno, SWITZERLAND;

Lisa Schnell, Zurich, SWITZERLAND;

Martin E Schwab, Zurich, SWITZERLAND;

Alessandra Vitaliti, Bedigliora, SWITZERLAND;

Mauro Zurini, Binningen, SWITZERLAND;

Power of Attorney: The patent practitioners associated with Customer Number 1095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/13960 12/09/2003

Foreign Applications

0228832. 2 GREAT BRITAIN 10/1a/a002

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No



Title

Antibody ("1107") Anti Nogo A And Its Phaemaceutical use

Nogo-a-binding molecules and pharmaceutical use thereof-

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

OIPE 403

ECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

×	Original		Supplemental		□s	ubstitute
				•		
As a	a below named invente	or, I hereby de	clare that:		•	
Му	residence, post office	address and o	citizenship are a	s stated below n	ext to my nai	me, and
and	elieve I am the original Joint inventor (if more ch a United States pat	than one nan	ne is listed belov	v) of the subject	listed below) matter which	or an original, first is claimed and for
AN	TIBODY ("11C7") AN	TI NOGO AN	D ITS PHARMA	CEUTICAL US	E ,	•
the	specification of which:		•			
	is attached hereto					
	was filed on	(day/mon	·	plication No.	· ·	
	and, if this box (□) contains an				
	was amen		y/month/year)			·
		/ <u>d</u> c	<i>y</i> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
×	was filed as Paten	t Cooperation	Treaty internati	ional Application	No.	
	PCT/ EP03/13960)		2.2003		·
			(day/mo	nth/year)		
	and, if this box (\Box) contains an	x			
	□ entered th	e national sta	ge in the United	States and was	accorded A	oplication No.
;	and, if this box (□) contains an	<u>*</u>			
• •	☐ was amen	ded, subsequ	ent to entry into	the national sta	ige, on	
		٠	•			(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) specifically referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose information which is material to patentability as defined in 37 C.F.R. 1.56, including, for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or Patent Cooperation Treaty international filing date of the continuation-in-part application.

I hereby claim the benefit under 35 U.S.C. 119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate listed below and under 35 U.S.C. 365(a) of any Patent C ooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORIT	CLAIMED		
Great Britain	0228832.2	10/12/2002	⊠ Yes	□ No		
	•		☐ Yes	□ No		
			☐ Yes	□ No		
			☐ Yes	□ No		
		•	☐ Yes	□ No		
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:						
APPLICATION NO.		FILING DATE (day/month/year)	• • • • • • • • • • • • • • • • • • • •			

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) listed below and under 35 U.S.C. 365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below:

United States	United States	Status (Pending,	International	
Application No.	Filing Date	Abandoned or U.S.	Application No. and Filing Date	
,	(day/month/year)	Patent No.)	(day/month/year)	



I hereby appoint all of the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If this box (□) contains an x 国, I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from Corporate Intellectual Property of Novartis International AG. Basle. Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please send all correspondence relating to this application to the address associated with Customer No. 001095.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first joint inventor	Carmen BARSKE	
Inventor's signature	Lam Barda	Date 15/6/2005 (day/month/year)
Residence	Loerrach, Germany	
Citizenship	citizen of Germany	
Post Office Address	Birkenweg 10 79540 Loerrach Germany	
Full name of second joint inventor, if any	Anis Khusro MIR	
Inventor's signature	Luis Klusso Mi	Date 5/6/2005 (day/month/year)
Residence	Bartenheim, France	
Citizenship	citizen of Great Britain	
Post Office Address	Rue des Vosges 6 68870 Bartenheim France	

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of third joint inventor, if any **Thomas OERTLE** Date Inventor's signature Gerra/Gambarogno, Switzerland Residence citizen of Switzerland Citizenship **Post Office Address** Casa al lago 6576 Gerra/Gambarogno **Switzerland** Full name of fourth joint inventor, if any Lisa SCHNELL of Rhull Date Inventor's signature (day/month/year) Residence Zürich, Switzerland citizen of Switzerland Citizenship Post Office Address Schwanengasse 9 8001 Zürich **Switzerland** Full name of fifth Martin E. SCHWAB joint inventor, if any Date Inventor's signature Residence Zürich, Switzerland citizen of Switzerland Citizenship Waffenplatz Strasse 79 BEYNINGS TV. 96 Post Office Address

2002 Zürich **Switzerland**

Full name of sixth joint inventor, if any

Alessandra VITALITI

Inventor's signature

e 10101

Date 24/06/05

Residence

Bedigliora, Switzerland

Citizenship

citizen of Switzerland

Post Office Address

Bedigliora Switzerland

Full name of seventh joint inventor, if any

Mauro ZURINI

Inventor's signature

Binningen, Switzerland

Residence Citizenship

citizen of Switzerland

Post Office Address

Benkenstrasse 92a 4102 Binningen Switzerland